The combination of tremelimumab, an anticytotoxic T-lymphocyte-associated antigen-4 (anti-CTLA-4) monoclonal antibody (Figure 6C), and durvalumab, an anti-PD-L1 monoclonal antibody (Figure 6B), has also been investigated in the treatment of advanced HCC. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.